References
- Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 67(4), 286–288 (2012).
- Wright GD. Resisting resistance: new chemical strategies for battling superbugs. Chem. Biol. 7(6), R127–R132 (2000).
- Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215–1218 (2009).
- Kurz S, Bonomo RA. Reappraising the use of b-lactams to treat tuberculosis. Expert Rev. Anti Infect. Ther. 10(9), 999–1006 (2012).
- Wolff KA, Nguyen L. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev. Anti Infect. Ther. 10(9), 971–981 (2012).
- Weber W, Schoenmakers R, Keller B et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105(29), 9994–9998 (2008).
- Willand N, Dirié B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537–544 (2009).
- Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, Syu W Jr. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J. Antimicrob. Chemother. 67(3), 633–637 (2012).
- Ong W, Sievers A, Leslie DE. Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob. Agents Chemother. 54(6), 2748; author reply 2748–2749 (2010).
- Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 53(11), 4789–4793 (2009).
- Barr J. A short history of dapsone, or an alternative model of drug development. J. Hist. Med. Allied Sci. 66(4), 425–467 (2011).
- Favrot L, Ronning DR. Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev. Anti Infect. Ther. 10(9), 1023–1036 (2012).
- Adams KN, Takaki K, Connolly LE et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145(1), 39–53 (2011).
- Viveiros M, Martins M, Rodrigues L et al. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev. Anti Infect. Ther. 10(9), 983–998 (2012).
- D’Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 477(7365), 457–461 (2011).
- Liu J, Gordon B. Targeting the global regulator Lsr2 as a novel approach for anti-tuberculosis drug development. Expert Rev. Anti Infect. Ther. 10(9), 1049–1053 (2012).
- Burian J, Ramón-García S, Howes CG, Thompson CJ. WhiB7, a transcriptional activator that coordinates physiology with intrinsic drug resistance in Mycobacterium tuberculosis. Expert Rev. Anti Infect. Ther. 10(9), 1037–1047 (2012).
- Jayachandran R, Scherr N, Pieters J. Elimination of intracellularly residing Mycobacterium tuberculosis through targeting of host and bacterial signaling mechanisms. Expert Rev. Anti Infect. Ther. 10(9), 1007–1022 (2012).
- Islam MS, Richards JP, Ojha AK. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev. Anti Infect. Ther. 10(9), 1055–1066 (2012).